Dr. Jeremy M. Levin
Dr. Jeremy M. Levin is a physician, scientist, biotechnology leader, and author of Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust. Over a decades-long career spanning science, medicine, pharmaceuticals, and biotechnology, Dr. Levin has become one of the industry’s leading voices on innovation, public trust, and the future of healthcare.
Background
Dr. Levin began his career studying the structure of DNA before practicing medicine in leading university hospitals in London, Cape Town, and Geneva. Those early experiences caring for patients shaped his enduring belief that drug discovery is not an abstract business, but a deeply human endeavor built around improving and saving lives.
Throughout his career, Dr. Levin has held leadership roles across some of the most influential organizations in global healthcare. At Bristol Myers Squibb, he pioneered the transformational “string of pearls” strategy that reshaped the company’s innovation pipeline through strategic partnerships and acquisitions. He later served as CEO of Teva Pharmaceuticals, the world’s largest generic drug manufacturer, before returning to biotechnology leadership at Ovid Therapeutics, where he championed the development of innovative therapies for complex neurological disorders.
Biotech in the Balance
Today, Dr. Levin is focused on advocating for a stronger, more resilient biotechnology ecosystem—one capable of sustaining scientific innovation, restoring public trust, and ensuring lifesaving medicines continue reaching patients in times of rapid political and societal change. Through his writing, speaking, and industry leadership, he continues to call for a biotechnology sector rooted in transparency, scientific rigor, long-term thinking, and a renewed commitment to patients.
At the core of Dr. Levin’s work is a simple conviction: biotechnology is not just an industry—it is a strategic asset fundamental to health, economic growth, and the future of society itself.
Follow